Cost-effectiveness of recombinant human erythropoietin versus transfusions in the treatment of zidovudine-related anemia in hiv-lnfected children

Pediatric AIDS and HIV Infection

Volumn 8, Issue 1, 1997, Pages 4-11

  Alien, Upton D ^a   Kirby, Melanie Ann ^a   Goeree, Ron ^a  

^a CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT ERYTHROPOIETIN; ZIDOVUDINE;

ANEMIA; ARTICLE; BLOOD TRANSFUSION; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; HOSPITAL COST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ADMINISTRATION; LABORATORY TEST; MEDICAL FEE; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

ANEMIA; ANTI-HIV AGENTS; BLOOD TRANSFUSION; CHILD; COST-BENEFIT ANALYSIS; DECISION TREES; ERYTHROPOIETIN; HEALTH CARE COSTS; HIV INFECTIONS; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); SENSITIVITY AND SPECIFICITY; ZIDOVUDINE;

EID: 0031004178     PISSN: 10455418     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Fischl M, Galpin JE, Levine JD, et al. Recombinant human erythropoietin for patients with AIDS treated with zidovudine. N Engl J Med 1990;322:1488-1493.
2. Connor E. Antiretroviral treatment for children with human immunodeficiency virus infection. Pediatr 1991;88:389-392.
3. Mueller BU, Jacobsen F, Jarosinski PD, et al. Erythropoietin for zidovudine-associated anemia in children with HIV infection. Ped AIDS and HIV Infect: Fetus to Adolescent 1994;5:169-173.
4. Drummond MF, Stoddart GL, Torrance GW. Methods for economic evaluation of health care programmes. Oxford: Oxford University Press, 1987.
5. Alien U, King S, Lapointe N, et al. Correlates of erythropoietin (EPO) profiles among HIV-infected children. Clin Infect Dis 1994;19:609(abst#276).
6. Henry DH, Beall GN, Benson ÇA et al. Recombinant human erythropoietin in the treatment of anemia associated with human immunodeficiency virus (HIV) infection and zidovudine therapy. Ann Int Med 1992;117:739-748.
7. Goeree R. A comparison of hospital costing techniques. Department of Clinical Epidemiology and Biostatistics document. Hamilton, Ontario, 1991.
8. Ministry of Health, Ontario, Canada. Schedule of benefits, under the Health Insurance Act. October, 1992.
9. Sheingold S, Churchhill D, Muirhead N, et al. The impact of recombinant human erythropoietin on medical care costs for hemodialysis patients in Canada. Soc Sci Med 1992;34:983-991.
10. Ortho Biotech Canada. A public briefing paper on the use of Recombinant Human Erythropoietin. Don Mills, Ontario 1991.
11. Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ. The risk of transfusion-transmitted viral infections. N Engl J Med 1996;334:1685-1690.
12. Cantor SB, Carson RW, Spann SJ. A cost-effectiveness analysis of Epoetin usage for patients with AIDS. PharmacoEconomics 1993;3:244-249.
13. Smith BR. Use of erythropoietin in AIDS and hématologie disorders. Hospital formulary 1989;246:892-96.